Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial-Reference-Cited by-同舟云学术

Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial

Published:2020-02-20 Issue:3 Volume:34 Page:381-393
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Su Jinmei,Li Mengtao,He Lan,Zhao Dongbao,Wan Weiguo,Liu Yi,Xu Jianhua,Xu Jian,Liu Huaxiang,Jiang Lindi,Wu Huaxiang,Zuo Xiaoxia,Huang Cibo,Liu Xiumei,Li Fen,Zhang Zhiyi,Liu Xiangyuan,Dong Lingli,Li Tianwang,Chen Haiying,Li Jingyang,He Dongyi,Lu Xin,Huang Anbin,Tao Yi,Wang Yanyan,Zhang Zhuoli,Wei Wei,Li Xiaofeng,Zeng Xiaofeng

Funder

Chinese National Key Technology R&D Program, Ministry of Science and Technology

Medicine and Health Technology Innovation Project, Chinese Academy of Medical Sciences

ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-020-00408-z.pdf

Reference26 articles.

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379–90. https://doi.org/10.1016/S0140-6736(07)60635-7.